Fairvalue-Calculator Fairvalue-Calculator

DaShenLin Pharmaceutical Group (603233) Fair Value & Analysis

Healthcare · CN · Market cap 19.1B CNY

Price¥15.87
Fair Value¥23.86
Upside+50.3%
Quality88/100
Evidence: Medium Range ¥17.90 – ¥31.00

Analysis

DaShenLin Pharmaceutical Group (603233) currently trades at ¥15.87, while our model-based Fair Value estimate is ¥23.86 — implying the stock looks roughly 50.3% undervalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.

Open the full interactive analysis →

Similar stocks

JD Health International Inc (JDHIF) +404% Alibaba Health Information Technology Limited (ALBBY) -20% Raia Drogasil S.A (RADL3) -8% Yifeng Pharmacy Chain Co (603939) +5% Clicks Group (CLCGY) +45% Sugi Holdings (SGIPF) +98%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.